Why the study?
This report appraised evidence for a patient with osteosarcoma regarding concerns about the risk of secondary malignant neoplasms that attend use of dexrazoxane.
Does dexrazoxane decrease cardiotoxic effects of doxorubicin without increasing mortality from secondary malignant neoplasms in patients with newly diagnosed nonmetastatic osteosarcoma?
Does dexrazoxane decrease cardiotoxic effects of doxorubicin without increasing mortality from secondary malignant neoplasms in patients with newly diagnosed nonmetastatic osteosarcoma?
Dexrazoxane decreases doxorubicin-induced cardiotoxicity in osteosarcoma patients without increasing mortality from secondary malignancies.
Answers are grounded in this paper and cite their sources.
Individualized dexrazoxane risk-benefit assessment remains essential in osteosarcoma; leaves open whether cardioprotection outweighs secondary neoplasm concerns.
A clinical decision report appraising: Schwartz CL, Wexler LH, Krailo MD, et al. Intensified chemotherapy with dexrazoxane cardioprotection in newly diagnosed nonmetastatic osteosarcoma: A report from the Children’s Oncology Group. Pediatr Blood Cancer. 2016;63(1):54-615. https://doi.org/10.1002/pbc.25753 for a patient with osteosarcoma and concerns about the risk of secondary malignant neoplasms that attend use of dexarazoxane.
No takes yet. Share an insight, caveat, or question.
Thomas S. Przybycien (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: